Exchanges NYSE

  • How should investors play the ups and downs in this volatile market? David Kelly, chief market strategist at JPMorgan Funds, shared his insights.

  • Carlyle’s deal to buy NBTY, the vitamin company, for $3.8 billion stopped me in my tracks. NBTY has been a long-standing tug-of-war stock between the longs and shorts.

  • Steve Jobs with an iPhone 4

    With a mushrooming iPhone antenna problem threatening to stain Apple's spotless image, the company has decided to hold a press conference Friday. Thanks to Consumer Reports' earnest call for action, a little slip in the stock price and a bit of Top Ten mockery from David Letterman this week, Apple has arrived at the so-called fork in the road.

  • bp140.jpg

    BP and Apache are closing in on a deal. Apache's financing for the deal is key. Bankers tell me the company is seeking a bridge loan between $6 and $7 billion for the purchase.

  • Shares of KKR, the parent of private equity firm Kohlberg Kravis Roberts, are finally trading on the New York Stock Exchange, three years after it initially sought the US listing.

  • Stocks were lower on Thursday following signs that the recovery remains tepid, even as companies report strong earnings. So where should investors look to put their money amidst the uncertainty? Jay Leupp at Grubb & Ellis AGA and Harry Clark of Clark Capital Management Group discussed their views.

  • Stocks fell on Thursday after disappointing manufacturing reports spread worries about the economic recovery. Barbara Marcin, portfolio manager at Gabelli Blue Chip Value Fund, shared her insights.

  • Here's something you can bank on. If the financials don't trade higher, this market is going nowhere fast.

  • Here's an interesting tidbit from the semiconductor world — and it has nothing to do with Intel, at least not yet.

  • Several Wall Street firms are looking to expand their asset-backed trading. UBS has added 350 new traders and salespeople over the last 12 months; Morgan Stanley has hired 250 people in new fixed income and is expected to hire 200 more.

  • Money in Mattress

    Simon Baker, the founder of Baker Avenue Asset Management, got his start managing wealth at big Wall Street firms. But the U.K.-born money manager bristles when presented with arguments for the traditional "buy and hold" methodology still touted by his various alma maters.

  • wall_st_sign_green.jpg

    Investors concerned about a double-dip can shield themselves with large-cap companies that have global reach and ample cash to withstand a slowdown.

  • Apple, Google, Amazon and Microsoft are the so called "Four Horsemen" of the tech stock world and sit in many porfolios. But what other tech stocks should investors consider? Kim Caughey, senior equity analyst at Fort Pitt Capital Group and Randy Bateman, chief investment officer at Huntington Funds, stopped by to offer their picks.

  • Markets opened lower on Wednesday after a report showed retail sales fell for a second straight month and report out of Europe that several banks will fail their stress tests. Madelynn Matlock, director of international investments at Huntington Funds and John Browne, senior market strategist at Euro Pacific Capital discussed their insights.

  • RadioShack

    Participants in that auction tell me, in recent days, it has slowed and while there was significant interest from PE initially, that interest is now being described as more modest, though bankers tell me a few sponsors continue to work on a deal.

  • BlackRock is out with its third quarter allocation report, and Robert Doll, BlackRock vice chairman, along with Curtis Arledge, BlackRock cio of fixed income, fundamental portfolios, gave their outlook on the economy and the markets.

  • Intel's conference call was about as optimistic and bullish as any I've heard.

  • Add Clorox to the "One Decision" stock member club because this company is so strong that the thought of selling won't enter your mind.

  • Flextronics has been flexing its muscle with a big rally this month, and now our screens are lighting up with bullish activity.

  • Big pharmaceutical companies have been beaten down by worries over patent expirations, a lack of new products and low price-to-earnings ratios. But health care strategists aren't all pessimistic.